Mature T-cell and NK-cell lymphomas: updates on molecular genetic features

[1]  S. Ishikawa,et al.  Clonal germinal center B cells function as a niche for T-cell lymphoma , 2022, Blood.

[2]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[3]  W. Chan,et al.  Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma , 2022, Leukemia.

[4]  L. Staudt,et al.  The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. , 2022, Blood.

[5]  T. Noda,et al.  Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma , 2022, Haematologica.

[6]  P. Gaulard,et al.  Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations , 2022, Modern Pathology.

[7]  Peggy Wu,et al.  T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  K. Naresh,et al.  Parallel evolution of two distinct lymphoid proliferations in clonal haematopoiesis , 2022, Histopathology.

[9]  C. Ong,et al.  Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS , 2022, Haematologica.

[10]  Hyunsung Kim,et al.  The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma , 2022, Life.

[11]  S. Miyano,et al.  Whole-genome landscape of adult T-cell leukemia/lymphoma. , 2021, Blood.

[12]  Nicholas D. Ward,et al.  Co-occurring rearrangements of DUSP22 and TP63 define a rare genetic subset of ALK-negative anaplastic large cell lymphoma with inferior survival outcomes , 2021, Leukemia & lymphoma.

[13]  H. Iwasaki,et al.  Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma , 2021, British journal of haematology.

[14]  Daniel‐Adriano Silva,et al.  Super-enhancer-based identification of a BATF3/IL-2R−module reveals vulnerabilities in anaplastic large cell lymphoma , 2021, Nature Communications.

[15]  F. Jardin,et al.  Detection of gene fusion transcripts in Peripheral T-cell Lymphoma using a multiplexed targeted sequencing assay. , 2021, The Journal of molecular diagnostics : JMD.

[16]  P. Gaulard,et al.  Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified , 2021, Nature Communications.

[17]  C. Ong,et al.  A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma. , 2021, Blood.

[18]  M. Arcila,et al.  Next generation sequencing of breast implant‐associated anaplastic large cell lymphomas reveals a novel STAT3‐JAK2 fusion among other activating genetic alterations within the JAK‐STAT pathway , 2021, The breast journal.

[19]  Š. Pospíšilová,et al.  STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma , 2020, Leukemia.

[20]  G. Bhagat,et al.  Combined Oral 5-Azacytidine and Romidepsin are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study. , 2020, Blood.

[21]  V. Seshan,et al.  T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. , 2020, Blood advances.

[22]  P. Campbell,et al.  CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) , 2020, Haematologica.

[23]  D. M. Miedema,et al.  Chromosome 20 loss is characteristic for Breast implant-Associated Anaplastic Large Cell Lymphoma. , 2020, Blood.

[24]  C. Gambacorti-Passerini,et al.  Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy , 2020, American journal of hematology.

[25]  C. Ong,et al.  Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. , 2020, Blood.

[26]  Dachuan Huang,et al.  Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma , 2020, Leukemia.

[27]  S. Chiba,et al.  Advances in understanding of angioimmunoblastic T-cell lymphoma , 2020, Leukemia.

[28]  M. Georges,et al.  Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype , 2020, Leukemia.

[29]  S. Kato,et al.  Nodal EBV+ cytotoxic T-cell lymphoma: A literature review based on the 2017 WHO classification , 2020, Journal of clinical and experimental hematopathology : JCEH.

[30]  D. de Jong,et al.  Increased prevalence of BRCA1/2 mutations in women with macro-textured breast implants and anaplastic large cell lymphoma of the breast. , 2020, Blood.

[31]  M. Arcila,et al.  Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. , 2020, Blood advances.

[32]  A. Feldman,et al.  Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma , 2020, Haematologica.

[33]  Ali F. Alsulami,et al.  Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target , 2020, Haematologica.

[34]  Weili Zhao,et al.  Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. , 2020, Cancer cell.

[35]  G. Follows,et al.  Angioimmunoblastic T‐cell lymphoma contains multiple clonal T‐cell populations derived from a common TET2 mutant progenitor cell , 2019, The Journal of pathology.

[36]  L. Staudt,et al.  Reproducing the Molecular Subclassification of Peripheral T-cell Lymphoma-NOS by Immunohistochemistry. , 2019, Blood.

[37]  L. Quintanilla‐Martinez,et al.  Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America , 2019, Modern Pathology.

[38]  K. Debackere,et al.  FER and FES tyrosine kinase fusions in follicular T-cell lymphoma. , 2019, Blood.

[39]  B. Ebert,et al.  Clonal hematopoiesis in human aging and disease , 2019, Science.

[40]  W. Park,et al.  Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression , 2019, Modern Pathology.

[41]  S. Pileri,et al.  Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large-cell lymphomas. , 2019, Human pathology.

[42]  R. Gascoyne,et al.  Identification of high‐risk DUSP22‐rearranged ALK‐negative anaplastic large cell lymphoma , 2019, British journal of haematology.

[43]  Jesse S. Voss,et al.  Recurrent MSC E116K mutations in ALK-negative anaplastic large cell lymphoma. , 2019, Blood.

[44]  S. Crotty.  T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. , 2019, Immunity.

[45]  T. Miyazaki,et al.  Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling , 2019, Leukemia.

[46]  S. Pileri,et al.  Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified , 2019, Modern Pathology.

[47]  L. Staudt,et al.  Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. , 2019, Blood.

[48]  O. Dereure,et al.  Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior , 2019, Virchows Archiv.

[49]  P. Gaulard,et al.  The pathological features of angioimmunoblastic T-cell lymphomas with IDH2R172 mutations , 2019, Modern Pathology.

[50]  A. Jeyasekharan,et al.  Molecular pathogenic pathways in extranodal NK/T cell lymphoma , 2019, Journal of Hematology & Oncology.

[51]  P. Gaulard,et al.  Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas , 2019, Leukemia.

[52]  Bo W. Han,et al.  Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma , 2018, Leukemia.

[53]  S. Fox,et al.  Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma , 2018, Oncotarget.

[54]  M. Piris,et al.  DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers , 2018, Haematologica.

[55]  K. Pradhan,et al.  North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. , 2018, Blood.

[56]  J. Cerhan,et al.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. , 2018, Blood.

[57]  R. D. Hatton,et al.  Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helper T cells , 2018, Science.

[58]  G. Bhagat,et al.  Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas , 2018, Modern Pathology.

[59]  L. Medeiros,et al.  Breast implant-associated anaplastic large cell lymphoma: a review , 2018, Modern Pathology.

[60]  J. Aster,et al.  RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. , 2018, Blood.

[61]  S. Iida,et al.  CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. , 2018, Blood.

[62]  A. Feldman,et al.  Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. , 2018, Blood.

[63]  P. Murray,et al.  Epstein-Barr Virus-Induced Epigenetic Pathogenesis of Viral-Associated Lymphoepithelioma-Like Carcinomas and Natural Killer/T-Cell Lymphomas , 2018, Pathogens.

[64]  Preti Jain,et al.  Targeted next generation sequencing of breast implant‐associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A , 2018, British journal of haematology.

[65]  A. Ferrando,et al.  RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. , 2018, Cancer cell.

[66]  J. Jen,et al.  Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma , 2017, Leukemia.

[67]  P. Gaulard,et al.  Activation of RHOA–VAV1 signaling in angioimmunoblastic T-cell lymphoma , 2017, Leukemia.

[68]  Dachuan Huang,et al.  Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. , 2017, Blood.

[69]  O. Nureki,et al.  Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. , 2015, Blood.

[70]  C. Ong,et al.  Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes , 2017, Haematologica.

[71]  D. Dunson,et al.  Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.

[72]  M. Matsuoka,et al.  Human T-cell leukaemia virus type 1: parasitism and pathogenesis , 2017, Philosophical Transactions of the Royal Society B: Biological Sciences.

[73]  A. Feldman,et al.  DUSP22 AND TP63 REARRANGEMENTS PREDICT OUTCOME OF ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A DANISH COHORT STUDY , 2017, Blood.

[74]  P. Gaulard,et al.  Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin , 2017, Haematologica.

[75]  I. Lossos,et al.  Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas , 2017, Proceedings of the National Academy of Sciences.

[76]  S. Miyano,et al.  Identification of cell-type-specific mutations in nodal T-cell lymphomas , 2017, Blood Cancer Journal.

[77]  P. Gaulard,et al.  The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development , 2016, Proceedings of the National Academy of Sciences.

[78]  Wen-Qi Jiang,et al.  PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma , 2016, Journal of Hematology & Oncology.

[79]  Ryan D. Morin,et al.  Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. , 2016, Blood.

[80]  Sarah H. Johnson,et al.  Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. , 2016, Blood.

[81]  Gisela Mir Arnau,et al.  Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma , 2016, Haematologica.

[82]  P. Kim,et al.  Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma , 2016, Haematologica.

[83]  Satoru Miyano,et al.  Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers , 2016, Nature.

[84]  Y. Ko,et al.  Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior , 2016, Modern Pathology.

[85]  P. Gaulard,et al.  DNMT3AR882H mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice , 2016, Leukemia.

[86]  P. Gaulard,et al.  Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  R. Rabadán,et al.  Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. , 2016, Blood.

[88]  H. Aburatani,et al.  Integrated molecular analysis of adult T cell leukemia/lymphoma , 2015, Nature Genetics.

[89]  T. Molina,et al.  Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets , 2015, Haematologica.

[90]  A. Rosenwald,et al.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. , 2015, Cancer cell.

[91]  W. Choi,et al.  Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma. , 2015, Blood.

[92]  L. Staudt,et al.  IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. , 2014, Blood.

[93]  L. Staudt,et al.  Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma , 2014, The Journal of experimental medicine.

[94]  K. Elenitoba-Johnson,et al.  A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. , 2014, Blood.

[95]  H. Aburatani,et al.  Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice , 2014, Blood Cancer Journal.

[96]  W. Wilson,et al.  ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. , 2014, Blood.

[97]  Min Kyung Sung,et al.  A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma , 2014, Nature Genetics.

[98]  O. Nureki,et al.  Somatic RHOA mutation in angioimmunoblastic T cell lymphoma , 2014, Nature Genetics.

[99]  P. Gaulard,et al.  JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma , 2014, Leukemia.

[100]  I. Lossos,et al.  Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas , 2014, Nature Genetics.

[101]  N. Harris,et al.  A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. , 2012, Blood.

[102]  L. Staudt,et al.  Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. , 2012, Blood.

[103]  A. Rosenwald,et al.  PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. , 2013, Blood.

[104]  W. Chan,et al.  MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. , 2013, Blood.

[105]  B. Nathwani,et al.  Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. , 2012, Blood.

[106]  David I. Smith,et al.  Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. , 2012, Blood.

[107]  Francesco Bertoni,et al.  Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. , 2012, Blood.

[108]  Ryan D. Morin,et al.  TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. , 2012, Blood.

[109]  W. Chan,et al.  IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. , 2012, Blood.

[110]  K. Karube,et al.  Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. , 2011, Blood.

[111]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[112]  A. Feldman,et al.  Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies , 2011, Modern Pathology.

[113]  M. Salto‐Tellez,et al.  Activated oncogenic pathways and therapeutic targets in extranodal nasal‐type NK/T cell lymphoma revealed by gene expression profiling , 2011, The Journal of pathology.

[114]  David I. Smith,et al.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. , 2011, Blood.

[115]  R. Greil,et al.  Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK− anaplastic large-cell lymphoma , 2010, Proceedings of the National Academy of Sciences.

[116]  P. Gaulard,et al.  Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. , 2010, Blood.

[117]  W. Chan,et al.  Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. , 2010, Blood.

[118]  R. deLeeuw,et al.  Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies , 2009, Leukemia.

[119]  M. Wasik,et al.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) , 2008, Proceedings of the National Academy of Sciences.

[120]  Stefano A Pileri,et al.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. , 2008, Blood.

[121]  R. Gascoyne,et al.  Genomic profiling reveals different genetic aberrations in systemic ALK‐positive and ALK‐negative anaplastic large cell lymphomas , 2008, British journal of haematology.

[122]  Christian Gisselbrecht,et al.  The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. , 2007, Blood.

[123]  R. Siebert,et al.  Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma , 2006, Leukemia.

[124]  H. Tagawa,et al.  Genome‐wide array‐based comparative genomic hybridization of natural killer cell lymphoma/leukemia: Different genomic alteration patterns of aggressive NK‐cell leukemia and extranodal Nk/T‐cell lymphoma, nasal type , 2005, Genes, chromosomes & cancer.

[125]  D. Levy,et al.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.

[126]  G. Delsol,et al.  Oncogenic protein tyrosine kinases , 2004, Cellular and Molecular Life Sciences CMLS.

[127]  D. Levy,et al.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death , 2002, Oncogene.

[128]  K. Ohshima,et al.  Nasal lymphomas in Japan: a high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene. , 1999, Leukemia & lymphoma.

[129]  H. Satoh,et al.  Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[130]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.